Search results
Results From The WOW.Com Content Network
The ESMO Clinical Practice Guidelines on Early and Metastatic Breast Cancer cover information on screening, diagnosis, pathology and molecular biology, staging and risk assessment, disease management, monitoring and follow-up, palliative care and the patient perspective. There are also specific guidelines focusing on risk reduction and ...
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35 (2):159-182. This ESMO Clinical Practice Guideline provides key recommendations and algorithms for the management of patients with EBC. It covers diagnosis, staging, risk assessment, treatment, follow-up, specific situations and the ...
NEW statement. The ESMO-MCBS scores for the use of a CDK4/6 inhibitor combined with endocrine therapy for ABC patients vary according to the setting and drug. They are the following, with the current available data and FU: PALBOCICLIB + AI 1st line: Efficacy score: 3 (PFS); No improved QoL; ESMO-MCBS = 3.
ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer. These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of breast cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges ...
LUGANO, Switzerland – The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer (1) has been published today in Annals of Oncology. Amidst public information and support initiatives taking place worldwide on the occasion of Breast Cancer Awareness Month, the ...
The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically relevant topics and are produced by 20-40 key experts in the field. ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
In Europe, there is a breast cancer diagnosis every 2 minutes and. a death due to breast cancer every 6 minutes. Breast cancer mostly affects older women, with the majority of patients being over the age of 50 when diagnosed, although around 1 in 5 breast cancers are diagnosed before the age of 50.
This manuscript summarises the ESO–ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA). Breast cancer in young women encompasses unique treatment and survivorship considerations. Fertility, ovarian function suppression and premature menopause are major issues that need ...
ESMO Expert Consensus Statements on on the definition, diagnosis, and management of HER2-low breast cancer. HER2-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical ...
The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of primary breast cancer and for the management of locally recurrent or metastatic breast cancer. This guide for patients has been produced in collaboration with ESMO and is ...